

Dimensional Securities Pvt Ltd.

Diwali Picks 2019, Samvat 2076

Date: 25th Oct,2019

HAPPY
DIWALI
FESTIVAL OF LIGHTS



Dimensional Securities Diwali Picks 2019, Samvat 2076

Stock	CMP	Target	Upside
ITC Ltd.	251	315	25.5%
HDFC Ltd.	2100	2400	14.3%
VRL Logistics	268	338	26.1%
Zydus Wellness	1689	2008	18.9%
Nocil	114	145	27.2%
S. H. Kelkar	132	156	18.2%

Harsh Shah

Research Analyst

Harsh.shah@dimensional.in

022-66545231

Jainis Chheda

Research Analyst

jainis.chheda@dimensional.in

022-66545239

Ravindra Bhandari

Head of research

ravindra@dimensional.in

022-66545256

ITC Ltd

ITC is the monopoly business in cigarette in India contributing more than 85% of the legal cigarette consumption along with significantly high tax consumption on tobacco in the country. Cigarette remain addictive consumption and demographic distribution of India will remain important factor for increasing cigarette consumption in the country. Number of cigarette consumption per capita in India is far lower compared to its immediate peers, this is due to differential tax treatment on other products. Hence, the affordability is lower on high cost cigarette. Affordability is improving as the disposable income for the middle class is increasing.

Other FMCG business of the company has achieved over Rs 12,500cr revenue in FY19. Among listed players, this is only lower to HUL Ltd and far higher than other major peers like Dabur, Marico, Godrej. Since ITC focus has been on achieving scale ahead of profitability, we see subdued EBIT margin in other FMCG business. We expect EBIT margin to gradually improve as the company gets economies of scale with increasing revenue.

Significant portion of Agri and paper business should be seen as support businesses to the cigarette due to large intersegment sales. Hotel and Paper segment is supported by limited supply in the industry.

Valuations: We Value ITC on a SoTP method, with each segment valued as per its competitive intensity and ITC bargaining power in the segment. Cigarette being a monopoly is valued at 16x EV/EBIT, is significantly lower than last 5yr average. Other FMCG business is valued at 5x EV/Sales as margin is currently on upmove and yet to stabilize. We value ITC at 315/share, 25% upside from the current price

Symbol	CMP	M. Cap	TTM P/E	2W Vol.
ITC	251.0	305872.0	22.0	16215.2

	ITC Ltd.		
Description	FY17	FY18	FY19
Net Sales	42776.6	43448.9	48352.7
EBITDA (Ex OI)	15460.6	16503.2	18425.4
Profit After Tax	10471.3	11485.1	12824.2
Adjusted EPS	8.5	9.2	10.3
ROE (%)	24.3	24.1	23.8
ROCE (%)	36.0	35.4	34.4
Debt/Equity(x)	0.0	0.0	0.0
Adjusted PE (x)	33.1	27.7	28.9
EV/EBITDA(x)	19.6	16.9	17.5

HDFC Ltd.

HDFC is India's largest provider of housing finance, primarily focusing on retail housing. HDFC's distribution network spans 392 outlets, which include 113 offices of HDFC's distribution company. In addition, HDFC covers additional locations through its outreach programmes, which has helped the corporation disburse housing loans in more than 2,400 towns and cities in India. It has also supplemented the distribution channel through the appointment of direct selling agents (DSA). Currently, 72.2% of the shares are held by foreign institutional investors/foreign direct investments and 10.0% by individuals.

With the current challenges in HFC and PSU banks, we believe business will gravitate towards franchise which has stronger balance sheet and distribution reach. HDFC, being the largest players in the fray will be leading beneficial in this transition.

Besides the core business of mortgages, HDFC has evolved into a financial conglomerate, diversifying into other businesses through its subsidiaries viz., HDFC Standard Life Insurance (51.6%), HDFC Asset Management Company (52.8%), HDFC Bank (21.4%), HDFC General Insurance Company (58.4%) and 10% in Bandhan Bank.

We value HDFC on a SoTP basis to arrive at target price of Rs 2,400, 14% upside to the current share price.

Symbol	CMP	M. Cap	TTM P/E	2W Vol.
HDFC	2100.0	363105.0	22.8	3380.3

	HDFC Ltd.		
Description	FY17	FY18	FY19
Interest Income	61034.0	79474.0	95694.0
Interest Expenses	21992.0	24764.0	29584.0
Operating Expenses	23791.0	37046.0	45067.0
PAT (inc share of Assoc)	11051.0	11980.0	16232.0
EPS	69.6	71.5	94.3
P/B	4.0	3.4	3.1
PE	21.6	25.5	20.9

Zydus Wellness Ltd. –

Zydus Wellness, the FMCG arm of the Cadila group, has created a niche for itself with a range of wellness and innovative products. Some of the main brands of the company include:

- * Sugar Free: It is a low calorie sweetener with over 80% market share in the category.
- * Nutralite: It is a zero cholesterol substitute for butter.
- * Everyuth: Market leader in peel off and scrub.

With increase in lifestyle diseases and more people searching for healthy alternatives, Zydus could be looking at a multi-year growth opportunity. The company continuously comes out with innovate offerings like new Sugarlite which has similar taste to sugar but has 50% lower calorie, Sugarfree Veda made from natural extracts of Elachi, Tulsi, and lemon and flavoured Nutralite Mayonnaise.

In Oct 2018, Zydus further strengthened its brand portfolio by acquiring Complian, Glucon-D and Nycil Powder from Heinz at an enterprise value of Rs. 4,600 cr, which was at a multiple of 20X EV/EBITDA. These brands were not key focus areas for Heinz, which led to loss of market share continuously. However, for Zydus, these brands form key part of its core business. It will cross-utilize its own and Heinz's existing distribution network, and would be aggressively adding more dealers as a part of its brand extension. This will aid the top line growth for the company, and given management's track record of efficiency, there is also a scope for margin expansion for these brands.

The company is also exploring international opportunity in geographies like Africa, South East Asia & SAARC. These markets can provide incremental growth to the company. Zydus is currently trading at a 1 Yr fwd P/E of 41X, which is at 25-30% discount to other FMCG players. Given the strong track record of the management, niche portfolio of brands and opportunities, we believe Zydus to be good portfolio buy.

Symbol	CMP	M. Cap	TTM P/E	2W Vol.
ZYDUS	1670.0	9629.0	44.2	13.5

	Zydus Wellness Ltd.		
Description	FY17	FY18	FY19
Net Sales	430.6	512.6	842.8
EBITDA (Ex OI)	99.1	125.3	174.4
Profit After Tax	111.3	136.5	171.2
Adjusted EPS	27.9	34.3	29.3
ROE (%)	21.5	21.9	8.4
ROCE (%)	23.5	23.3	7.1
Debt/Equity(x)	0.0	0.0	0.5
Adjusted PE (x)	31.2	34.2	44.3
EV/EBITDA(x)	22.6	26.2	41.7

VRL Logistics Ltd.

VRL Logistics Ltd. (VRL) is a well-established surface transportation brand in the country when and the industry leader in Less-than-Truck-Load space. VRL operates with a fleet size of 4,400 trucks with over 697 branches, 195 agencies and 46 trans-shipment hubs, giving it a huge scale and wide network to work with.

VRL has fair amount of dealings with SME & MSME sector which is going through a rough phase, owing to which company is seeing some stagnation in its volume. Adding to that are the woes of other manufacturing industries like automobiles, auto ancillaries, textiles, etc. company has not been able to grow its volume over last two years. However, given VRL's dominant position in the LTL industry, we believe that it'll see a strong uptick in its volume once the recovery sets in.

Over the last few years, due to strings of policy decisions like demonetization, GST and e-way bill, the balance in the logistics industry has shifted in the favour of organized players like VRL, who has been able to sustain their business despite overall slowdown, while many SFOs have gone out of the business.

The trucking industry is largely dominated by Full-Truck-Load (FTL) segment which forms nearly 88% of the road industry. However, VRL has carved out huge market share in the LTL segment which forms 10% of the industry but is expected to grow at a faster rate. The upcoming DFCC, which will be a huge negative for FTL players, will be beneficial to LTL players like VRL as demand for short distance last mile delivery will go up.

Currently, company's business is at the bottom of the business cycle and we expect recovery to set in with the base also being favourable. We are valuing VRL at 20X FY21's normalized EPS of Rs. 16.9 to arrive at our target price of Rs. 338 for the stock, which presents a potential upside of 23% from the CMP of Rs. 273.

Symbol	CMP	M. Cap	TTM P/E	2W Vol.
VRLLG	268.0	2375.0	24.9	36.9

	VRL Logistics Ltd.		
Description	FY17	FY18	FY19
Net Sales	1803.1	1922.3	2109.5
EBITDA (Ex OI)	215.9	234.8	244.5
Profit After Tax	70.5	92.6	91.9
Adjusted EPS	7.7	10.2	10.2
ROE (%)	13.4	16.3	14.8
ROCE (%)	17.3	21.6	20.8
Debt/Equity(x)	0.3	0.1	0.2
Adjusted PE (x)	40.3	37.5	27.7
EV/EBITDA(x)	13.4	14.2	10.6

NOCIL Ltd.

An Arvind Mafatlal Group enterprise, Nocil is India's largest rubber chemicals manufacturer, having manufacturing facilities at Navi Mumbai and Dahej. In FY18 Nocil had capacity of 55,000 MTPA for rubber chemicals (including capacity for intermediates) operating at 95% utilization levels. NOCIL doubled its capacity taking the total capacity to 1,10,000 MTPA expected to be operational by H2FY20.

Automobile industry consumes ~80% of the total rubber manufactured. Tyre specifically consumes ~65% of the total rubber. Growth in automobile sector will lead to growth in rubber consumption thereby increase demand for rubber chemicals. The key advantage for NOCIL is that EV disruption in automobile sector will remain unaffected for the company

On back of improved manufacturing process at Dahej and technological advancement, NOCIL has been able to expand its gross profit margin by 1990 bps over last 5 years. Also, the company has focused on production of high margin premium products which make the higher margin sustainable going forward.

We are valuing NOCIL at 12X FY22's normalized EPS of Rs 12 to arrive at our target price of Rs. 144 for the stock, which presents a potential upside of 31% from the CMP of Rs 110. Accordingly, we recommend a BUY on the stock.

Symbol	CMP	M. Cap	TTM P/E	2W Vol.
NOCIL	114.0	1826.0	11.1	749.1

	Nocil Ltd.		
Description	FY17	FY18	FY19
Net Sales	742.2	967.6	1042.9
EBITDA (Ex OI)	159.2	265.4	292.7
Profit After Tax	97.1	169.9	184.9
Adjusted EPS	5.9	10.3	11.2
ROE (%)	14.1	17.4	16.8
ROCE (%)	20.8	25.9	25.1
Debt/Equity(x)	0.0	0.0	0.0
Adjusted PE (x)	15.8	18.5	13.2
EV/EBITDA(x)	8.5	11.1	7.9

S H Kelkar

S H Kelkar (SHK) is Flavors & Fragrances (F&F) manufacturing company. Globally top 10 F&F companies command ~78% market share. F&F has various applications such as packaged foods, detergents, soaps, cents etc. However, cost of F&F ingredient in final product is typically in range of 0.5%-2%. Since the value terms contribution in final product is so small, undercutting from here will not be possible.

SHK owns ~13% market share in domestic F&F market, mainly contributed by unorganized segment. The company has 40-50% capacity utilization in Fragrance segment thereby having sufficient headroom to cater to additional demand. SHK spending 2.5-3% of revenue towards R&D while the global spends stands at 6-7% of sales annually. Moreover, SHK has 12 molecules patented.

90% of revenue contribution is from Fragrances segment, SHK holds 23% market share. The segment is expected to grow at 10%. 10% of revenue contribution is from Flavors segment, SHK holds 2% market share and the same is expected to grow at 20-25% due to lower base. Due to number of factors disrupting raw materials supply, the prices escalated and inventory got piled up with SHK. Going forward the inventory levels are expected to come down. EBITDA margin post normalization is expected to be stable in range of 16-18% compared to 12% EBITDA margin in FY19.

We recommend a buy on S H Kelkar with a target price of Rs. 156

Symbol	CMP	M. Cap	TTM P/E	2W Vol.
SHK	132.0	1962.0	22.3	116.5

	SH Kelkar & Co Ltd.		
Description	FY17	FY18	FY19
Net Sales	980.5	1021.0	1043.6
EBITDA (Ex OI)	166.9	159.4	133.7
Profit After Tax	104.8	92.6	87.8
Adjusted EPS	7.2	6.5	6.1
ROE (%)	13.7	11.1	10.2
ROCE (%)	18.8	15.5	11.7
Debt/Equity(x)	0.1	0.2	0.4
Adjusted PE (x)	41.1	39.8	25.1
EV/EBITDA(x)	24.2	21.0	15.6

ANALYST CERTIFICATION

We, Research Analysts, authors and the names subscribed to this report; hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & conditions and other disclosures:

Dimensional Securities Private Limited (DSPL) is engaged in the business of stock broking and distribution of financial products. This Report has been prepared by Dimensional Securities Private Limited (DSPL) in the capacity of a Research Analyst having SEBI Registration No. INH000001444 and distributed as per SEBI (Research Analysts) Regulations 2014.

The information and opinions in this report have been prepared by DSPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of DSPL. While we would endeavour to update the information herein on a reasonable basis, DSPL is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent DSPL from doing so.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. DSPL or its associates accept no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

DSPL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. DSPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither DSPL nor Research Analysts have any material conflict of interest at the time of publication of this report.

It is confirmed that , Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. DSPL or its associates collectively or Research Analysts do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of DSPL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

It is confirmed that , Research Analysts do not serve as an officer, director or employee of the companies mentioned in the report.

DSPL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. We submit that no material disciplinary action has been taken on DSPL by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject DSPL and associates to any registration or licensing requirement within such jurisdiction.

The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

DSPL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of DSPL to present the data. In no event shall DSPL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by DSPL through this report.